Get started
Work

CSF biomarkers for Alzheimer’s pathology and the effect size of APOE ɛ4

Year: 2013
Type: article
Study design: Observational Study
Abstract: New research and clinical criteria for Alzheimer’s disease (AD) have recently been proposed, which include biomarker information on Alzheimer’s plaque and tangle pathology, or AD-typical structural brain changes, as supporting or essential elements of an AD diagnosis. 1 , 2 , 3 In a large group of patients with both genetic and cerebrospinal fluid (CSF) biomarker data, we here show that biomarker-assisted diagnosis-making almost doubles the effect size of the association between the ɛ4 variant of the apolipoprotein E ( APOE ) gene and AD.
DOI: 10.1038/mp.2013.18
Authors: U Andreasson, R Lautner, J M Schott, N Mattsson, O Hansson, S-K Herukka, S Helisalmi, M Ewers, H Hampel, A Wallin, L Minthon, J Hardy, K Blennow, H Zetterberg
Institutions: University of Gothenburg, UCL Queen Square Institute of Neurology, University College London, Lund University, University of Eastern Finland, Institut für Schlaganfall- und Demenzforschung, Ludwig-Maximilians-Universität München, Goethe University Frankfurt
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,490
Funders: Alzheimer's Association, Demensförbundet, EU Joint Programme – Neurodegenerative Disease Research, National Institute for Health and Care Research, University College London, Wolfson Foundation, Science Foundation Ireland, Vetenskapsrådet, Swedish Brain Power, University College London Hospitals NHS Foundation Trust
Awards: G153995592, G1681703157, G1729430826, G3256776521, G3392527931, Targeted Proteomics of Cerebrospinal Fluid Amyloid-Beta Fragments in Alzheimer's Disease, G4876679765, G5829058750, G610756488, CSET APC: Alimentary Pharmabiotic Centre - Second Term Funding, G6745615612
OpenAlex ID: W2073554622
FWCI: 3.628
Cites: 7
Cited by: 29
Related to: 10